BeginNGS – Newborn Genomic Sequencing to End the Diagnostic Odyssey with Dr. Stephen Kingsmore, Wendy Erler and Tom DeFay
ONCE UPON A GENE – EPISODE 221
BeginNGS – Newborn Genomic Sequencing to End the Diagnostic Odyssey with Dr. Stephen Kingsmore, Wendy Erler and Tom DeFay
I’m joined by Dr. Stephen Kingsmore, Wendy Erler and Tom DeFay to discuss BeginNGS, a ground-breaking initiative that stands at the forefront of genetic sequencing and rare disease diagnosis.
EPISODE HIGHLIGHTS
What led to the creation of BeginNGS?
Rare genetic diseases are an immense health ecosystem challenge- receiving a timely diagnosis. On average, it takes 4.8 years to diagnose a child with a genetic disease, and meanwhile, symptoms continue to worsen and the disease progresses. The goal of BeginNGS is to prevent or reduce the impact on children with rare genetic diseases, minimizing suffering, cost and delay of diagnosis.
Why is BeginNGS an important initiative to support?
Anyone connected to the rare disease community shares the same vision for a world where every rare disease patient receives the right effective treatment at the right time. That starts with changing the diagnostic odyssey and ensuring early, fast diagnosis.
What is the mission of the BeginNGS Consortium?
The BeginNGS Consortium is a partnership of pharmaceutical and biotech companies, sharing a vision of the right effective treatment at the right time. Our vision is ultimately to ensure every baby born in the United States has the opportunity to be screened for rare disorders. What differentiates this program and the consortium is that the patient communities have been represented from the beginning and the patient population communities has been impressive. Some of our working groups are led by members of the patient community to make sure that what’s delivered is valuable to the patients.
What are the major pain points to leveraging newborn screening for preventable disorders and broad use of rapid diagnostic genome sequencing?
Pediatricians rarely order genome sequencing. We estimate only 2% of children who need the testing get it. Additionally, even when testing is ordered, it doesn’t always translate into optimal treatments and there can still be delays in life-saving treatments.
What does the future look like for BeginNGS?
The BeginNGS Consortium is comprised of rare disease advocacy organizations, parent support groups, healthcare systems, policy makers, experts in academic medicine, biotech companies developing new genome sequencing methods and pharmaceutical companies developing new treatments for rare genetic diseases. We hope to increase the size of the consortium so we can grow the organization and capture every voice and represent every genetic disease. Another strong aspiration is to raise grant support and funding to complete and deploy our pivotal clinical trial.
LINKS AND RESOURCES MENTIONED
https://radygenomics.org/begin-ngs-newborn-sequencing/
ONCE UPON A GENE – EPISODE 213 – Finding Strength In Every Step
https://effieparks.com/podcast/episode-213-finding-strength-in-every-step
https://radygenomics.org/frontiers-conference/
CONNECT WITH EFFIE PARKS
https://twitter.com/OnceUponAGene
https://www.instagram.com/onceuponagene.podcast/?hl=en
